PH12022550963A1 - Anti-hemagglutinin antibodies and methods of use thereof - Google Patents

Anti-hemagglutinin antibodies and methods of use thereof

Info

Publication number
PH12022550963A1
PH12022550963A1 PH1/2022/550963A PH12022550963A PH12022550963A1 PH 12022550963 A1 PH12022550963 A1 PH 12022550963A1 PH 12022550963 A PH12022550963 A PH 12022550963A PH 12022550963 A1 PH12022550963 A1 PH 12022550963A1
Authority
PH
Philippines
Prior art keywords
antibodies
influenza
methods
bind
preventing
Prior art date
Application number
PH1/2022/550963A
Other languages
English (en)
Inventor
Alina Baum
Christos Kyratsous
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PH12022550963A1 publication Critical patent/PH12022550963A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
PH1/2022/550963A 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof PH12022550963A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US202063094170P 2020-10-20 2020-10-20
PCT/US2020/057635 WO2021086899A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12022550963A1 true PH12022550963A1 (en) 2023-09-25

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550963A PH12022550963A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Country Status (14)

Country Link
US (2) US11773156B2 (https=)
EP (1) EP4051707A1 (https=)
JP (1) JP7611908B2 (https=)
KR (1) KR20220088446A (https=)
CN (1) CN114761428A (https=)
AU (2) AU2020374878B2 (https=)
BR (1) BR112022007923A2 (https=)
CA (1) CA3153944A1 (https=)
CL (1) CL2022001067A1 (https=)
CO (1) CO2022005281A2 (https=)
IL (1) IL292353A (https=)
MY (1) MY207220A (https=)
PH (1) PH12022550963A1 (https=)
WO (1) WO2021086899A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201306A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating influenza infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
KR102228296B1 (ko) * 2012-03-16 2021-03-17 리제너론 파마슈티칼스 인코포레이티드 히스티딘 공학처리된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-사람 동물
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) * 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
EA201691945A1 (ru) * 2014-03-27 2017-02-28 Дженентек, Инк. Антитела к гемагглютинину вируса гриппа типа b и способы их применения
CN119161468A (zh) * 2014-07-15 2024-12-20 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN113480640B (zh) 2015-06-01 2024-07-30 免疫医疗有限责任公司 中和抗流感结合分子及其用途
US10696736B2 (en) * 2015-06-03 2020-06-30 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR102820941B1 (ko) * 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체

Also Published As

Publication number Publication date
EP4051707A1 (en) 2022-09-07
AU2025271140A1 (en) 2026-01-22
JP2022553703A (ja) 2022-12-26
US11773156B2 (en) 2023-10-03
AU2020374878B2 (en) 2025-10-16
WO2021086899A1 (en) 2021-05-06
US20240083983A1 (en) 2024-03-14
AU2020374878A1 (en) 2022-04-28
CN114761428A (zh) 2022-07-15
IL292353A (en) 2022-06-01
US20210171612A1 (en) 2021-06-10
BR112022007923A2 (pt) 2022-07-26
MY207220A (en) 2025-02-06
KR20220088446A (ko) 2022-06-27
CL2022001067A1 (es) 2023-01-27
CO2022005281A2 (es) 2022-05-10
JP7611908B2 (ja) 2025-01-10
CA3153944A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
PH12018502673A1 (en) Anti-zika virus antibodies and methods of use
EP4653051A3 (en) Human antibodies to ebola virus glycoprotein
PH12020551051A1 (en) Human antibodies to influenza hemagglutinin
WO2020106358A8 (en) Novel anti-zika virus antibodies and uses thereof
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
PH12022550963A1 (en) Anti-hemagglutinin antibodies and methods of use thereof
WO2014160171A3 (en) Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
ECSP21039816A (es) Anticuerpos monoclonales antirrábicos y cóctel de estos
HK1238655A1 (en) Human antibodies to influenza hemagglutinin
EA201990300A1 (ru) Антитела к вирусу зика и способы их применения
HK1240605A1 (zh) 针对埃博拉病毒糖蛋白的人抗体
EA202191973A3 (ru) Человеческие антитела к гликопротеину вируса эбола
MA40375B1 (fr) Anticorps humains contre l'hémagglutinine de la grippe